These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 7641411

  • 1. Effects of quinagolide (CV 205-502), a selective D2-agonist, on vascular reactivity in patients with a prolactin-secreting adenoma.
    Bodmer CW, Atkin SL, Savage MW, Masson EA, White MC.
    Clin Endocrinol (Oxf); 1995 Jul; 43(1):49-53. PubMed ID: 7641411
    [Abstract] [Full Text] [Related]

  • 2. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
    Di Sarno A, Landi ML, Marzullo P, Di Somma C, Pivonello R, Cerbone G, Lombardi G, Colao A.
    Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
    [Abstract] [Full Text] [Related]

  • 3. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
    Colao A, Ferone D, Lastoria S, Cerbone G, Di Sarno A, Di Somma C, Lucci R, Lombardi G.
    Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
    [Abstract] [Full Text] [Related]

  • 4. In vivo imaging of pituitary tumours using a radiolabelled dopamine D2 receptor radioligand.
    de Herder WW, Reijs AE, Kwekkeboom DJ, Hofland LJ, Nobels FR, Oei HY, Krenning EP, Lamberts SW.
    Clin Endocrinol (Oxf); 1996 Dec; 45(6):755-67. PubMed ID: 9039343
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Diagnosis and drug therapy of prolactinoma.
    Ciccarelli E, Camanni F.
    Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
    [Abstract] [Full Text] [Related]

  • 10. Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization.
    Colao A, Di Somma C, Loche S, Di Sarno A, Klain M, Pivonello R, Pietrosante M, Salvatore M, Lombardi G.
    Clin Endocrinol (Oxf); 2000 Mar; 52(3):319-27. PubMed ID: 10718830
    [Abstract] [Full Text] [Related]

  • 11. Prolactin decrease and shift to a normal-like isoform profile during treatment with quinagolide in a patient affected by an invasive prolactinoma.
    Guido R, Valenti S, Foppiani L, De Martini D, Cossu M, Giusti M.
    J Endocrinol Invest; 1997 May; 20(5):289-93. PubMed ID: 9258810
    [Abstract] [Full Text] [Related]

  • 12. Treatment of macroprolactinoma with the new potent non-ergot D2-dopamine agonist quinagolide and effects on prolactin levels, pituitary function, an the renin-aldosterone system. Results of a clinical long-term study.
    Nickelsen T, Jungmann E, Althoff P, Schumm-Draeger PM, Usadel KH.
    Arzneimittelforschung; 1993 Apr; 43(4):421-5. PubMed ID: 8098604
    [Abstract] [Full Text] [Related]

  • 13. Comparison among different dopamine-agonists of new formulation in the clinical management of macroprolactinomas.
    Colao A, Merola B, Sarnacchiaro F, Di Sarno A, Landi ML, Marzullo P, Cerbone G, Ferone D, Lombardi G.
    Horm Res; 1995 Apr; 44(5):222-8. PubMed ID: 8582715
    [Abstract] [Full Text] [Related]

  • 14. Effect of the new dopaminergic agonist CV 205-502 on plasma prolactin levels and tumour size in bromocriptine-resistant prolactinomas.
    Duranteau L, Chanson P, Lavoinne A, Horlait S, Lubetzki J, Kuhn JM.
    Clin Endocrinol (Oxf); 1991 Jan; 34(1):25-9. PubMed ID: 1672268
    [Abstract] [Full Text] [Related]

  • 15. Effect of dopamine agonists on prolactinomas and normal pituitary assessed by dynamic contrast enhanced magnetic resonance imaging (DCE-MRI).
    Manuchehri AM, Sathyapalan T, Lowry M, Turnbull LW, Rowland-Hill C, Atkin SL.
    Pituitary; 2007 Jan; 10(3):261-6. PubMed ID: 17557207
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Late development of resistance to bromocriptine in a patient with macroprolactinoma.
    Delgrange E, Crabbé J, Donckier J.
    Horm Res; 1998 Jan; 49(5):250-3. PubMed ID: 9568811
    [Abstract] [Full Text] [Related]

  • 18. [Treatment of prolactinoma with a new dopamine agonist].
    Svoboda T, Luger A, Knosp E, Geyer G.
    Dtsch Med Wochenschr; 1991 Aug 16; 116(33):1224-7. PubMed ID: 1678695
    [Abstract] [Full Text] [Related]

  • 19. Long-term treatment of bromocriptine-intolerant prolactinoma patients with CV 205-502.
    Glaser B, Nesher Y, Barziliai S.
    J Reprod Med; 1994 Jun 16; 39(6):449-54. PubMed ID: 7932398
    [Abstract] [Full Text] [Related]

  • 20. The effect of aripiprazole and quinagolide, a dopamine agonist, in a patient with symptomatic pituitary prolactinoma and chronic psychosis.
    Broekhof R, Gosselink MJ, Pijl H, Giltay EJ.
    Gen Hosp Psychiatry; 2012 Jun 16; 34(2):209.e1-3. PubMed ID: 21872335
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.